Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment

Last updated: November 8, 2022
Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
Overall Status: Active - Recruiting

Phase

4

Condition

Hepatitis B

Hepatitis

Liver Failure

Treatment

N/A

Clinical Study ID

NCT05382013
PL16
  • Ages 18-65
  • All Genders

Study Summary

This study aims to investigate the efficacy and safety of avatrombopag for treating thrombocytopenia in hepatitis b virus related acute-on-chronic liver failure patients receiving artificial liver support system treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age from 18 to 65 years old;
  2. Clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis bsurface antigen or positive hepatitis b virus DNA > 0.5 year);
  3. Clinical diagnosis of liver failure (serum total bilirubin level > 10 times upperlimit of normal; prothrombin time activity < 40% and ≥20%, or prothrombin timeinternational ratio ≤ 2.6 and > 1.5);
  4. Platelets < 8010 E9/L and > 5010 E9/L.
  5. Signed informed consent form.

Exclusion

Exclusion Criteria:

  1. Other active liver diseases;
  2. Hepatocellular carcinoma or other malignancy;
  3. Pregnancy or lactation;
  4. Human immunodeficiency virus infection or congenital immune deficiency diseases;
  5. Severe diabetes, autoimmune diseases; unstable infarction due tocardio-cerebrovascular events; other important organ dysfunctions or transplantation;
  6. Severe complications including severe infection, gastrointestinal bleeding, hepaticencephalopathy, hepatorenal syndrome;
  7. Patients with ALSS treatment in one week;
  8. Thrombotic disease;
  9. Patients can not follow-up;
  10. Investigator considering inappropriate.

Study Design

Total Participants: 60
Study Start date:
April 27, 2022
Estimated Completion Date:
April 30, 2024

Study Description

Artificial liver support system (ALSS) is an optimal therapy in patients with hepatitis b virus (HBV) related acute-on-chronic liver failure (ACLF). But a lot of patients encount thrombocytopenia (TCP) due to the mechanical damage of thrombocyte and use of heparin during the treatment. Avatrombopag is an oral thrombopoietin receptor agonist that has been recently approved for treating TCP in chronic liver disease patients needing invasive procedures. Therefore, this study aims to investigate the efficacy and safety of avatrombopag for treating TCP in HBV related ACLF patients receiving ALSS treatment. Sixty patients with HBV related ACLF receiving ALSS will be enrolled in this study. The participants are divided into trial group (avatrombopag, double plasma molecular adsorption system (DPMAS) , low volume plasma exchange (LPE), and comprehensive internal medical treatment) and control group (DPMAS, LPE, comprehensive internal medical treatment). Symptoms, signs, laboratory tests results, adverse events, mortality rates are recorded from treatment baseline to 3 weeks.

Connect with a study center

  • Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong 510630
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.